A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis

Annals of Oncology

Volumn 7, Issue 9, 1996, Pages 945-952

  Olver, I ^a   Paska, W ^b   Depierre, A ^c   Seitz, J F ^d   Stewart, D J ^e   Goedhals, L ^f   McQuade, B ^b   McRae, J ^b   Wilkinson, J R ^b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e OTTAWA REGIONAL CANCER CENTRE   (Canada)

^f National Hospital Bloemfontein   (South Africa)

Author keywords

5 HT3 receptor antagonist; cisplatin; delayed emesis and nausea; dexamethasone; ondansetron

Indexed keywords

CISPLATIN; DEXAMETHASONE; ONDANSETRON; PLACEBO;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0030468309     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010798     Document Type: Article

References (23)

1. Kris MG, Gralla RJ, Clark RA et al. Incidence course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3: 1379-84.
2. De Mulder PHM, Seynaeve C, Vermerken JB et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834-40.
3. Marty M, Pouillart P, Scholl S et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816-21.
4. Morran C, Smith DC, Andersen DA, McArdle CS. Incidence of nausea and vomiting with cytotoxic chemotherapy: A prospective randomised trial of anti-emetics. BMJ 1979; 1879: 1323-4.
5. Martin Jimenez M, Diaz-Rubio E, Blazquez Encinar JC et al. Tolerancia, toxicidad y aceptacion del tratamiento quimioterapico FAC (5-fluorouracilo, adriamicina y ciciofosfamida) en el cancer de mama, Analsis de 100 pacientes consecutivas. Neoplasia 1988; 5: 8-14.
6. Kris MG, Gralla RJ, Tyson LB et al. Controlled delayed vomiting: Double-blind, randomised trial comparing placebo, dexamethasone alone and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7:108-14.
7. Allan SG, Cornbleet MA, Warrington PS et al. Dexamethasone and high-dose metoclopramide: Efficacy in controlling cisplatin induced nausea and vomiting. BMJ 1984; 289: 878-9.
8. Roila F, Tonato M, Cognetti F et al. Prevention of cisplatin-induced emesis: A double-blind, multicentre, randomised, cross-over study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675-8.
9. Smyth JF, Coleman RE, Nicolson M et al. Does dexamethasone enhance control of acute cisplatin-induced emesis by ondansetron? BMJ 1991; 303: 1423-6.
10. Italian Group for Anti-emetic Research. Difference in persistence of efficacy of two anti-emetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993; 11(12): 2396-404.
11. Cunningham D, Dicato M, Verweij J et al. Optimum antiemetic therapy for cisplatin-induced emesis over repeat courses: Ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. Ann Oncol 1996; 7: 277-82.
12. Grunberg SM, Groshen S, Stevenson LL et al. Double-blind, randomised study of 2 doses of oral ondansetron (GR38032F) for the prevention of cisplatin-induced delayed nausea and vomiting. Proc Am Soc Clin Oncol 1990; 9: 327 (Abstr 1264).
13. Gandara DR. Progress in the control of acute and delayed emesis induced by cisplatin. Eur J Cancer 1991; 27 (Suppl 1): S9-S11.
14. Kris MG, Tyson LB, Clark RA et al. Oral ondansetron for the control of delayed emesis after cisplatin. Cancer 1992; 70: 1012-6.
15. Italian Group for Anti-emetic Research. Ondansetron + dexamethasone vs. metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 1992; 340: 96-9.
16. Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 1983; 25(1): 1-7.
17. Lindley CM, Hirsch JD, O'Neill CV et al. Quality of life consequences of chemotherapy-induced emesis. Qualify of Life Res 1992; 1: 331-40.
18. Soukop M, McQuade B, Hunter E et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 1992; 49: 295-304.
19. Smyth J. Delayed emesis after high-dose cisplain - the residual problem. Proceedings of the SmithKline Beecham Satellite Symposium to the XVII Congress of the European Society for Medical Oncology 1992; 24-26.
20. Navari MN, Madajewicz S, Andersen N et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: A large, multicentre, double-blind, randomised, comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13(9): 2408-16.
21. Coates A, Abraham S, Kaye S et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Oncol 1983; 19: 203-8.
22. Roila F, De Angelis V, Contu A et al. Ondansetron versus metoclopramide both combined with dexamethasone in the prevention of cisplatin-induced delayed emesis. Proc Am Soc Clin Oncol 1996; 15: 528 (Abstr 1705).
23. Roila F, Boschetti E, Tonato M et al. Predictive factors of delayed emesis in cisplatin-treated patients and anti-emetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol 1991; 14: 238-42.